Literature DB >> 12390516

Inhibition of lipopolysaccharide-induced cyclooxygenase-2, tumor necrosis factor-alpha and [Ca2+]i responses in human microglia by the peripheral benzodiazepine receptor ligand PK11195.

Hyan B Choi1, C Khoo, Jae K Ryu, Edo van Breemen, Seung U Kim, James G McLarnon.   

Abstract

The anti-inflammatory actions of the mitochondrial peripheral benzodiazepine receptor (PBR) agonist PK11195 [1-(2-chloro- phenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline-carboxamide] were investigated in human microglia. Application of the microglial inflammatory stimulus lipopolysaccharide (LPS, at 100 ng/mL for 3 h), induced enhancement of the expressions of the inducible enzyme, cyclooxygenase-2 (COX-2) and the pro-inflammatory cytokine, tumor necrosis factor-alpha (TNF-alpha). PK11195 (at 50 microm) significantly inhibited the LPS-induced up-regulation of both inflammatory factors; at a lower concentration of PK11195 (2 microm) expression of TNF-alpha, but not COX-2, was reduced. Production of both factors, using immunocytochemistry for COX-2 and ELISA for TNF-alpha, was markedly reduced with 50 microm of PK11195 added to LPS solution. Acute application of LPS induced a transient increase in intracellular Ca2+[Ca2+]i exhibiting both a slow development and recovery in kinetic behavior. This increase in [Ca2+]i consisted primarily of a Ca2+ influx component accompanied by a smaller mobilization from intracellular Ca2+ stores. In the presence of PK11195, the amplitude of the [Ca2+]i response induced by LPS was reduced by 54%. Another mitochondrial agent cyclosporin A (CsA), which also acts at the permeability transition pore (PTP) of mitochondrial membrane but at a site different from the PBR, was ineffective in reducing either the LPS-induced expression of COX-2 and TNF-alpha or the endotoxin increase in [Ca2+]i. These results indicate that the mitochondrial effector PK11195 is a specific and effective agent for inhibiting LPS-induced microglial expressions of COX-2 and TNF-alpha and that modulation of Ca2+-mediated signaling pathways could be involved in the anti-inflammatory actions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12390516     DOI: 10.1046/j.1471-4159.2002.01122.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  33 in total

1.  [(11)C]DAC-PET for noninvasively monitoring neuroinflammation and immunosuppressive therapy efficacy in rat experimental autoimmune encephalomyelitis model.

Authors:  Lin Xie; Tomoteru Yamasaki; Naotsugu Ichimaru; Joji Yui; Kazunori Kawamura; Katsushi Kumata; Akiko Hatori; Norio Nonomura; Ming-Rong Zhang; Xiao-Kang Li; Shiro Takahara
Journal:  J Neuroimmune Pharmacol       Date:  2011-10-29       Impact factor: 4.147

2.  Translocator protein (18 kDa)/peripheral benzodiazepine receptor specific ligands induce microglia functions consistent with an activated state.

Authors:  Judy Choi; Masataka Ifuku; Mami Noda; Tomás R Guilarte
Journal:  Glia       Date:  2011-02       Impact factor: 7.452

Review 3.  Neurosteroidogenesis Today: Novel Targets for Neuroactive Steroid Synthesis and Action and Their Relevance for Translational Research.

Authors:  P Porcu; A M Barron; C A Frye; A A Walf; S-Y Yang; X-Y He; A L Morrow; G C Panzica; R C Melcangi
Journal:  J Neuroendocrinol       Date:  2016-02       Impact factor: 3.627

4.  Overexpression of translocator protein in inflammatory bowel disease: potential diagnostic and treatment value.

Authors:  Mariano A Ostuni; Leeyah Issop; Gabriel Péranzi; Francine Walker; Magali Fasseu; Carole Elbim; Vassilios Papadopoulos; Jean-Jacques Lacapere
Journal:  Inflamm Bowel Dis       Date:  2010-09       Impact factor: 5.325

5.  Lipopolysaccharide-induced down-regulation of Ca2+ release-activated Ca2+ currents (I CRAC) but not Ca2+-activated TRPM4-like currents (I CAN) in cultured mouse microglial cells.

Authors:  Andreas Beck; Reinhold Penner; Andrea Fleig
Journal:  J Physiol       Date:  2007-11-08       Impact factor: 5.182

6.  Expression of the translocator protein of 18 kDa by microglia, macrophages and astrocytes based on immunohistochemical localization in abnormal human brain.

Authors:  M Cosenza-Nashat; M-L Zhao; H-S Suh; J Morgan; R Natividad; S Morgello; S C Lee
Journal:  Neuropathol Appl Neurobiol       Date:  2008-12-11       Impact factor: 8.090

7.  Ligand for translocator protein reverses pathology in a mouse model of Alzheimer's disease.

Authors:  Anna M Barron; Luis M Garcia-Segura; Donatella Caruso; Anusha Jayaraman; Joo-Won Lee; Roberto C Melcangi; Christian J Pike
Journal:  J Neurosci       Date:  2013-05-15       Impact factor: 6.167

8.  The translocator protein (TSPO) ligand PK11195 induces apoptosis and cell cycle arrest and sensitizes to chemotherapy treatment in pre- and post-relapse neuroblastoma cell lines.

Authors:  Maria C Mendonça-Torres; Stephen S Roberts
Journal:  Cancer Biol Ther       Date:  2013-01-28       Impact factor: 4.742

Review 9.  Translocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotrauma.

Authors:  Vassilios Papadopoulos; Laurent Lecanu
Journal:  Exp Neurol       Date:  2009-05-04       Impact factor: 5.330

10.  Macroglia-microglia interactions via TSPO signaling regulates microglial activation in the mouse retina.

Authors:  Minhua Wang; Xu Wang; Lian Zhao; Wenxin Ma; Ignacio R Rodriguez; Robert N Fariss; Wai T Wong
Journal:  J Neurosci       Date:  2014-03-05       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.